ADMA Biologics Inc vs First Citizens BancShares Inc — how do they compare? ADMA Biologics Inc trades at $9.36 (market cap $2.19B), while First Citizens BancShares Inc trades at $2,273.65 (market cap $25.26B). The key difference: First Citizens BancShares Inc is far larger — about 11.5× ADMA Biologics Inc's market cap, and First Citizens BancShares Inc pays a 0.37% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | FCNCA | |
|---|---|---|
Market Cap | $2.19B | $25.26B |
Sector | Health | Sector/Thematic |
52-Week High | $20.38 | $2.27K |
52-Week Low | $7.60 | $1.64K |
Enterprise Value | $2.26B | — |
Dividend Yield | — | 0.37% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.78, up 0.31% today, with a bullish technical signal from moving averages and strong fundamentals including a 32.98% net income margin and 41.9% ROE. Recent earnings show a mix of beats and misses, with Q3 2026 EPS expected at $0.19. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by news outlets in August 2026.
Outlook is cautiously optimistic due to robust profitability and analyst support, but legal risks and recent earnings volatility pose challenges. Investment opportunity hinges on legal resolution and sustained earnings growth, with risks including litigation outcomes and competitive pressures in the biologics sector.
First Citizens BancShares (FCNCA) trades at $2,271.31, up 1.7% on the day, with a bullish technical signal from moving averages and recent earnings beats. The stock shows strong fundamentals with a P/E of 12.08 and net income margin of 25.23%, supported by consistent revenue around $9.3B. Recent news highlights expansion in commercial lending and strategic leadership appointments, reinforcing growth initiatives.
Outlook remains positive due to earnings momentum and dividend stability, but risks include elevated uninsured deposits and net interest margin pressure. Analyst consensus is cautious with 82% hold ratings, suggesting limited near-term upside despite a $2,310 price target. Investors should weigh solid profitability against sector headwinds and valuation constraints.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →